down arrow

Anavex Life Sciences Corp.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0327973006
USD
4.45
0.78 (21.25%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

4.294.58

52 Week

2.8614.44
Valuation
Technical
Day's Volume

CASH

1.87 M

Shareholding (Mar 2025)

FII

4.34%

Held by 71 FIIs

DII

79.98%

Held by 19 DIIs

Promoter

0.12%

How big is Anavex Life Sciences Corp.?

22-Jun-2025

As of Jun 18, Anavex Life Sciences Corp. has a market capitalization of 761.52 million and reported net sales of 0.00 million with a net profit of -47.14 million. Shareholder's Funds are 120.26 million and Total Assets are 135.57 million.

As of Jun 18, Anavex Life Sciences Corp. has a market capitalization of 761.52 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -47.14 million during the same period.<BR><BR>As of Sep 24, the reporting period shows Shareholder's Funds of 120.26 million and Total Assets of 135.57 million.

Read More

What does Anavex Life Sciences Corp. do?

22-Jun-2025

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics for neurodegenerative and neurodevelopmental diseases. It has a market cap of $761.52 million and reported a net loss of $11 million in its most recent quarter.

Overview:<BR>Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics for neurodegenerative and neurodevelopmental diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: Not available<BR>Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025)<BR>Market-cap: USD 761.52 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.16<BR>Return on Equity: -47.26%<BR>Price to Book: 7.63<BR><BR>Contact Details:<BR>Address: 51 W 52nd St Fl 7th, NEW YORK NY: 10019-6163<BR>Tel: 1 800 6893939<BR>Website: https://www.anavex.com

Read More

Who are in the management team of Anavex Life Sciences Corp.?

22-Jun-2025

As of March 2022, Anavex Life Sciences Corp. is led by Dr. Christopher Missling as CEO, with a Board of Directors that includes five independent members: Dr. Peter Donhauser, Mr. Elliot Favus, Mr. Athanasios Skarpelos, Dr. Steffen Thomas, and Dr. Claus van der Velden.

As of March 2022, the management team of Anavex Life Sciences Corp. includes Dr. Christopher Missling, who serves as the President, Chief Executive Officer, Secretary, and Director. Additionally, the Board of Directors features several independent directors: Dr. Peter Donhauser, Mr. Elliot Favus, Mr. Athanasios Skarpelos, Dr. Steffen Thomas, and Dr. Claus van der Velden. <BR><BR>In summary, as of March 2022, Anavex Life Sciences Corp. is led by Dr. Christopher Missling, with a Board that includes five independent directors.

Read More

Is Anavex Life Sciences Corp. technically bullish or bearish?

20-Sep-2025

As of August 14, 2025, Anavex Life Sciences Corp. has a mildly bullish trend, with daily moving averages supporting this stance, despite weekly indicators showing mild bearishness, and while it underperformed the S&P 500 in the short term, it outperformed over the past year.

As of 14 August 2025, the technical trend for Anavex Life Sciences Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating mild bullishness, while the monthly MACD and KST are bullish. However, weekly indicators such as MACD, Bollinger Bands, and Dow Theory show mildly bearish signals. The stock has underperformed against the S&P 500 in the short term, with a -9.50% return over the past week compared to the S&P 500's 1.05%, but it has outperformed over the past year with a 57.64% return versus the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 803 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.11

stock-summary
Return on Equity

-52.89%

stock-summary
Price to Book

8.83

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-13 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-53.21%
0%
-53.21%
6 Months
-43.24%
0%
-43.24%
1 Year
-50.45%
0%
-50.45%
2 Years
-41.22%
0%
-41.22%
3 Years
-63.07%
0%
-63.07%
4 Years
-73.87%
0%
-73.87%
5 Years
-10.28%
0%
-10.28%

Anavex Life Sciences Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Anavex Life Sciences Corp. technically bullish or bearish?

As of 14 August 2025, the technical trend for Anavex Life Sciences Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating mild bullishness, while the monthly MACD and KST are bullish. However, weekly indicators such as MACD, Bollinger Bands, and Dow Theory show mildly bearish signals. The stock has underperformed against the S&P 500 in the short term, with a -9.50% return over the past week compared to the S&P 500's 1.05%, but it has outperformed over the past year with a 57.64% return versus the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-30.20%
EBIT to Interest (avg)
-45.52
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.16
Sales to Capital Employed (avg)
0
Tax Ratio
3.92%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
40.83%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
7.08
EV to EBIT
-10.70
EV to EBITDA
-10.70
EV to Capital Employed
-36.86
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-47.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 34 Schemes (15.56%)

Foreign Institutions

Held by 71 Foreign Institutions (4.34%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -8.20% vs -7.96% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.50",
          "val2": "-14.70",
          "chgp": "1.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.20",
          "val2": "-12.20",
          "chgp": "-8.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2024 is 0.00% vs 0.00% in Sep 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2024 is 9.47% vs 1.04% in Sep 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-52.90",
          "val2": "-55.80",
          "chgp": "5.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "1.00",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-43.00",
          "val2": "-47.50",
          "chgp": "9.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-14.50
-14.70
1.36%
Interest
0.00
0.00
Exceptional Items
0.00
0.10
-100.00%
Consolidate Net Profit
-13.20
-12.20
-8.20%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -8.20% vs -7.96% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Sep'24stock-summary
Sep'24
Sep'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-52.90
-55.80
5.20%
Interest
0.00
1.00
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-43.00
-47.50
9.47%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Sep 2024 is 0.00% vs 0.00% in Sep 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Sep 2024 is 9.47% vs 1.04% in Sep 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Anavex Life Sciences Corp. stock-summary
stock-summary
Anavex Life Sciences Corp.
Pharmaceuticals & Biotechnology
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including drug candidates to treat Alzheimer's disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer. Its research and development pipeline includes a clinical drug candidate and various compounds in different stages of pre-clinical study. Its product pipeline also includes ANAVEX 2-73, ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. The Company's SIGMACEPTOR Discovery Platform produces small molecule drug candidates with modes of action, based on its understanding of sigma receptors. ANAVEX 1-41 is a sigma-1 agonist. ANAVEX 1066 is a mixed sigma-1/sigma-2 ligand. As of September 30, 2016, the Company had not generated any revenues from its operations.
Company Coordinates stock-summary
Company Details
51 W 52nd St Fl 7th , NEW YORK NY : 10019-6163
stock-summary
Tel: 1 800 6893939
stock-summary
https://www.anavex.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."